Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline

Depression and Anxiety

Volumn 19, Issue 3, 2004, Pages 180-186

  Joyce, Peter R ^a   Mulder, Roger T ^a   McKenzie, Janice M ^a   Luty, Suzanne E ^a   Cloninger, C Robert ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical depression; Rejection sensitivity; Temperament; Treatment response

Indexed keywords

FLUOXETINE; NORTRIPTYLINE;

ADULT; ARTICLE; ATYPICAL DEPRESSION; BIPOLAR II DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOMES RESEARCH; PERSONALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; SOCIAL ADAPTATION; SUICIDE ATTEMPT; TEMPERAMENT;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; MALE; NORTRIPTYLINE; PSYCHIATRIC STATUS RATING SCALES; SEX FACTORS; TEMPERAMENT; TREATMENT OUTCOME;

EID: 2542481713     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20001     Document Type: Article

References (24)

1. Cloninger CR. 1986. A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev 4:167-226.
2. Cloninger CR, Pryzbeck TR, Svrakic DM, Wetzel RD. 1994. The Temperament and Character Inventory (TCI): A guide to its development and use. St. Louis, MO: Center for Psychobiology of Personality, Washington University.
3. Cloninger CR, Svrakic DM, Przybeck TR. 1993. A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975-990.
4. Davidson J, Pelton S. 1986. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 17:87-95.
5. Derogatis L. 1983. SCL-90-R Administration, scoring and procedures manual. Baltimore, MD.
6. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
7. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger CR. 2003. Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response and six month outcome. Compr Psychiatry 44:35-43.
8. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF. 2002. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 36:384-391.
9. Lam RW, Stewart JN. 1996. The validity of atypical depression in DSM-IV. Compr Psychiatry 37:375-383.
10. Liebowitz MR, Klein DF. 1979. Hysteroid dysphoria. Psychiatr Clin North Am 2:555-576.
11. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Welikson K, Rabkin J, Nunes EN, Wager SG, Tricamo E, Quitkin FM, Klein DE 1992. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 12:197-202.
12. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DE 2000. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 157:344-350.
13. Montgomery SA, Asberg MA. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
14. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF. 1996. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 40:1017-1020.
15. Parker G, Hadzi-Pavlovic D. 1996. Melancholia: A disorder of movement and mood. New York: Cambridge University Press.
16. Paykel ES, Parker RR, Penrose RJ, Rassaby ER. 1979. Depressive classification and prediction of response to phenelzine. Br J Psychiatry 134:572-581.
17. Paykel ES, Parker RR, Rowan PR, Rao BM, Taylor CN. 1983. Nosology of atypical depression. Psychol Med 13:131-139.
18. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E. 1991. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 48:319-323.
19. Robinson DS, Nies A, Ravaris CL, Lamborn KL. 1973. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch Gen Psychiatry 29:407-413.
20. Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The structured clinical interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 49:624-629.
21. Stewart JW, McGrath PJ, Quitkin FM. 1992. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Am J Psychiatry 149:615-619.
22. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager SG, Liebowitz MR. 1989. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 46:1080-1087.
23. Weissman MM, Bothwell S. 1976. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 33:1111-1115.
24. West ED, Dally PJ. 1959. Effect of iproniazid in depressive syndromes. Br Med J 1:1491-1494.